Secondary prevention of myocardial infarction: an uncertain feeling.
作者信息
Hart J T, Barley S L
出版信息
J R Coll Gen Pract. 1982 Nov;32(244):651-3.
Abstract
摘要
相似文献
1
Secondary prevention of myocardial infarction: an uncertain feeling.心肌梗死的二级预防：一种不确定的感觉。
J R Coll Gen Pract. 1982 Nov;32(244):651-3.
2
[Secondary prevention after myocardial infarction].[心肌梗死后的二级预防]
Lakartidningen. 1978 May 17;75(20):2038-44.
3
The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
Mt Sinai J Med. 1984 Jun;51(3):229-36.
4
[Beta-blockers and secondary prevention after myocardial infarction].[心肌梗死后的β受体阻滞剂与二级预防]
Therapie. 1984 Mar-Apr;39(2):189-96.
5
[Secondary prevention after myocardial infarction--beta blockade and acetylsalicylic acid is the basic therapy].
Lakartidningen. 1989 Jan 4;86(1-2):47-50.
6
[Comparative study of verapamil and bisoprolol in the secondary prevention of myocardial infarction].
Orv Hetil. 1997 Aug 3;138(31):1939-45.
7
[Secondary prevention of myocardial infarction with beta-blockers: for how many?].β受体阻滞剂用于心肌梗死的二级预防：适用多久？
Harefuah. 1987 Feb 1;112(3):116-8.
8
[Adrenergic beta receptor blockaders as a secondary prevention after acute myocardial infarction].
Ugeskr Laeger. 1981 Nov 23;143(48):3241-5.
9
[Secondary prevention following a myocardial infarct].
Union Med Can. 1983 Mar;112(3):219-20, 225-8, 234.
10
[Secondary prevention of myocardial infarct by beta blockers, a myth or reality?].[β受体阻滞剂对心肌梗死的二级预防：是神话还是现实？]
Ann Med Interne (Paris). 1983;134(4):286-7.
本文引用的文献
1
Secondary prevention of myocardial infarction--the present state of the ART.心肌梗死的二级预防——抗栓治疗的现状
Br Med J. 1980 May 3;280(6223):1128-30. doi: 10.1136/bmj.280.6223.1128.
2
Multicentre post-infarction trial of propranolol in 49 hospitals in the United Kingdom, Italy, and Yugoslavia.在英国、意大利和南斯拉夫的49家医院进行的普萘洛尔心肌梗死后多中心试验。
Br Heart J. 1980 Jul;44(1):96-100. doi: 10.1136/hrt.44.1.96.
3
Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction.在疑似心肌梗死即刻治疗中比较普萘洛尔与阿替洛尔的随机试验。
Br Med J. 1980 Mar 29;280(6218):885-8. doi: 10.1136/bmj.280.6218.885.
4
Clinical policies.临床政策。
Br Med J (Clin Res Ed). 1982 Jul 31;285(6338):351-2. doi: 10.1136/bmj.285.6338.351.
5
Practice policy.实践政策。
Br Med J (Clin Res Ed). 1982 Jul 17;285(6336):177-9. doi: 10.1136/bmj.285.6336.177.
6
One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial.心肌梗死后使用普萘洛尔进行一年治疗：挪威多中心试验的初步报告。
Br Med J (Clin Res Ed). 1982 Jan 16;284(6310):155-60. doi: 10.1136/bmj.284.6310.155.
7
Should every survivor of a heart attack be given a beta-blocker? Part III. Some conclusions.每位心脏病发作幸存者都应该服用β受体阻滞剂吗？第三部分。一些结论。
Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):39-40. doi: 10.1136/bmj.285.6334.39.
8
Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint.每位心脏病发作幸存者都应服用β受体阻滞剂吗？第二部分。来自临床药理学角度的证据。
Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):37-9. doi: 10.1136/bmj.285.6334.37.
9
Should every survivor of a heart attack be given a beta-blocker? Part I. Evidence from clinical trials.每位心脏病发作幸存者都应服用β受体阻滞剂吗？第一部分。来自临床试验的证据。
Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):33-6. doi: 10.1136/bmj.285.6334.33.
10
Anticoagulants in coronary heart disease--retrospect and prospect.冠心病中的抗凝剂——回顾与展望
Lancet. 1981 Jan 31;1(8214):257-62. doi: 10.1016/s0140-6736(81)92095-x.
Zotero 插件